<?xml version="1.0" encoding="UTF-8"?>
<jcr:root xmlns:jcr="http://www.jcp.org/jcr/1.0" xmlns:cq="http://www.day.com/jcr/cq/1.0" xmlns:mix="http://www.jcp.org/jcr/mix/1.0" xmlns:nt="http://www.jcp.org/jcr/nt/1.0" xmlns:sling="http://sling.apache.org/jcr/sling/1.0"
          jcr:primaryType="cq:Page">
  <jcr:content
    cq:template="/apps/wcm-io-samples/sample-app/templates/content/content"
    jcr:primaryType="cq:PageContent"
    jcr:title="Overwhelming post-splenectomy infection"
    sling:resourceType="/apps/wcm-io-samples/sample-app/components/content/page/content">
    <content
      jcr:primaryType="nt:unstructured"
      sling:resourceType="wcm-io/wcm/parsys/components/parsys">
      <contentheadline
        jcr:primaryType="nt:unstructured"
        sling:resourceType="wcm-io-samples/sample-app/components/content/common/contentHeadline"
        headline="Overwhelming post-splenectomy infection" />
      <contentrichtext
        jcr:primaryType="nt:unstructured"
        sling:resourceType="wcm-io-samples/sample-app/components/content/common/contentRichText"
        text="&lt;p&gt;An &amp;apos;&amp;apos;&amp;apos;overwhelming post-splenectomy infection&amp;apos;&amp;apos;&amp;apos; (&amp;apos;&amp;apos;&amp;apos;OPSI&amp;apos;&amp;apos;&amp;apos;) is a rare but rapidly fatal [[infection]] occurring in individuals following removal of the [[spleen]]. The infections are typically characterized by either [[meningitis]] or [[sepsis]], and are caused by [[bacterial capsule|encapsulated organisms]] including &amp;apos;&amp;apos;[[Streptococcus pneumoniae]]&amp;apos;&amp;apos;.&amp;lt;ref name=&amp;quot;pmid11253134&amp;quot;&amp;gt;{{cite journal |author=Waghorn DJ |title=Overwhelming infection in asplenic patients: current best practice preventive measures are not being followed |journal=Journal of Clinical Pathology |volume=54 |issue=3 |pages=214–8 |year=2001 |month=March |pmid=11253134 |pmc=1731383 |doi= 10.1136/jcp.54.3.214|url=http://jcp.bmj.com/cgi/pmidlookup?view=long&amp;amp;pmid=11253134}}&amp;lt;/ref&amp;gt;

The risk of OPSI is 0.23&amp;amp;ndash;0.42 percent per year, with a lifetime risk of 5 percent.&amp;lt;ref name=&amp;quot;pmid11843905&amp;quot;&amp;gt;{{cite journal |author=Davidson RN, Wall RA |title=Prevention and management of infections in patients without a spleen |journal=Clinical Microbiology and Infection |volume=7 |issue=12 |pages=657–60 |year=2001 |month=December |pmid=11843905 |doi= 10.1046/j.1198-743x.2001.00355.x|url=http://www3.interscience.wiley.com/resolve/openurl?genre=article&amp;amp;sid=nlm:pubmed&amp;amp;issn=1198-743X&amp;amp;date=2001&amp;amp;volume=7&amp;amp;issue=12&amp;amp;spage=657}}&amp;lt;/ref&amp;gt; Most infections occur in the first few years following [[splenectomy]], but the risk of OPSI is lifelong.&amp;lt;ref name=&amp;quot;pmid11253134&amp;quot;/&amp;gt;&amp;lt;ref name=&amp;quot;pmid2070242&amp;quot;&amp;gt;{{cite journal |author=Cullingford GL, Watkins DN, Watts AD, Mallon DF |title=Severe late postsplenectomy infection |journal=The British Journal of Surgery |volume=78 |issue=6 |pages=716–21 |year=1991 |month=June |pmid=2070242 |doi= 10.1002/bjs.1800780626|url=}}&amp;lt;/ref&amp;gt; OPSI is nearly uniformly fatal without treatment, and modern treatment has decreased the mortality to approximately 40&amp;amp;ndash;70 percent.&amp;lt;ref name=&amp;quot;pmid11253134&amp;quot;/&amp;gt;&amp;lt;ref name=&amp;quot;pmid7131680&amp;quot;&amp;gt;{{cite journal |author=Schwartz PE, Sterioff S, Mucha P, Melton LJ, Offord KP |title=Postsplenectomy sepsis and mortality in adults |journal=Journal of the American Medical Association |volume=248 |issue=18 |pages=2279–83 |year=1982 |month=November |pmid=7131680 |doi= 10.1001/jama.248.18.2279|url=}}&amp;lt;/ref&amp;gt; Individuals with OPSI are most commonly treated with [[antibiotic]]s and supportive care.&amp;lt;ref name=&amp;quot;pmid11843905&amp;quot;/&amp;gt; Measures to prevent OPSI include vaccination and prophylactic antibiotics.&amp;lt;ref name=&amp;quot;pmid11843905&amp;quot;/&amp;gt;&amp;lt;ref name=&amp;quot;BMJ1996&amp;quot;&amp;gt;{{cite journal | author= | title=Guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen. Working Party of the British Committee for Standards in Haematology Clinical Haematology Task Force | journal=BMJ | year=1996 | pages=430–4 | volume=312 | issue=7028 | pmid=8601117 | url=http://bmj.bmjjournals.com/cgi/content/full/312/7028/430 | pmc= 2350106 | doi=10.1136/bmj.312.7028.430}}&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;BMJ2001&amp;quot;&amp;gt;{{cite journal | author=J M Davies | title=The Prevention And Treatment Of Infection In Patients With An Absent Or Dysfunctional Spleen - British Committee for Standards in Haematology Guideline up-date | journal=BMJ | date=2001-06-02 | url=http://bmj.bmjjournals.com/cgi/eletters/312/7028/430#12088 | author-separator=, | display-authors=1 | author2=&amp;lt;Please add first missing authors to populate metadata.&amp;gt;}}&amp;lt;/ref&amp;gt;

==Mechanism==
The [[spleen]] contains many [[macrophage]]s (part of the [[reticuloendothelial system]]), which are immune cells that [[phagocytose]] (eat) and destroy [[bacteria]].  In particular, these macrophages are activated when bacteria are bound by [[IgG]] [[antibodies]] (IgG1 or IgG3) or the [[Complement system|complement]] component C3b.  These types of antibodies and complements are immune substances called [[opsonizer]]s, molecules that bind to the surface of bacteria to facilitate [[phagocytosis]].

When the spleen is no longer present ([[asplenia]]), IgG and C3b are still bound to bacteria, but they cannot be removed from the [[blood]] circulation due to the loss of the splenic macrophages.  Hence the bacteria are free to cause [[infection]].

Patients without spleens often need [[immunization]]s against [[pathogen]]s that normally require [[opsonization]] and phagocytosis by macrophages in the spleen.  These include common human pathogens with [[bacterial capsules]] (&amp;apos;&amp;apos;[[Streptococcus pneumoniae]], [[Salmonella typhi]], [[Neisseria meningitidis]], [[E. coli]], [[Hemophilus influenzae]], [[Streptococcus agalactiae]], [[Klebsiella pneumoniae]]&amp;apos;&amp;apos;).  Capsules made of [[polysaccharide]]s (sugars) are an evolutionary development by bacteria to evade phagocytosis by macrophages alone, since only [[protein]]s are directly recognized by macrophages in phagocytosis.  So [[humoral]] immunity in forms of IgG and complement proteins is the [[human immune system]]&amp;apos;s response against bacterial capsules.

==References==
{{reflist|2}}

[[Category:Bacterial diseases]]
[[Category:Medical emergencies]]&lt;/p&gt;" />
    </content>
  </jcr:content>
</jcr:root>
